The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1/2 study of combination therapy with pexidartinib and sirolimus to target tumor-associated macrophages in malignant peripheral nerve sheath tumors.
 
Gulam Abbas Manji
Research Funding - Merck (Inst)
 
Parag Patwardhan
No Relationships to Disclose
 
Shing Mirn Lee
No Relationships to Disclose
 
Nanette Matos
No Relationships to Disclose
 
Edward Bentlyewski
No Relationships to Disclose
 
Brian Andrew Van Tine
Consulting or Advisory Role - Advaxis; Caris Life Sciences; DFINE; EMD Serono; GlaxoSmithKline; Johnson & Johnson; Lilly/ImClone; Novartis; Threshold Pharmaceuticals
Speakers' Bureau - Caris Life Sciences; DFINE; GlaxoSmithKline
Research Funding - Morphotek; Polaris
 
Khanh Tu Do
No Relationships to Disclose
 
Suzanne George
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie (I)
Consulting or Advisory Role - ARIAD; Blueprint Medicines; Novartis; Pfizer
Research Funding - ARIAD (Inst); Bayer (Inst); Blueprint Medicines (Inst); Novartis (Inst); Pfizer (Inst)
 
Gary K. Schwartz
Honoraria - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Novartis
Patents, Royalties, Other Intellectual Property - Patent pending regarding development of PNAs for targeted cancer therapy (new technology)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Novartis